Engineered immune cells target brain tumors in early trial
NCT ID NCT03696030
First seen Apr 26, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This early-phase study tests a new treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The treatment involves taking the patient's own immune cells, modifying them to recognize and attack HER2-positive cancer cells, and delivering them directly into the brain's fluid spaces. The main goals are to find the safest dose and understand side effects. About 24 adults with recurrent brain or leptomeningeal metastases are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.